U.S. Markets closed

AVI BioPharma: Eteplirsen study shows no significant improvement in walking

AVI BioPharma's study on treatment with Eteplirsen met its primary efficacy endpoint study in in boys with Duchenne muscular dystrophy, DMD, however, the stock is trading down 26% at mid-morning after failing to show a significant increase in novel dystrophin in a shorter duration 12 -week Eteplirsen study, which showed no significant improvements in clinical outcomes in the treated groups compared to placebo. Performance on the 6-minute walk test and other outcome measures were generally stable across most of the patients, including the placebo patients, suggesting that a longer period of observation will be required to demonstrate clinical effects of eteplirsen versus a placebo control.